Osteopore Limited

Osteopore Signs Non-Binding Term Sheet With CellHeal Which Will Commit AUD 10M To Accelerate Commercialisation In China

Australian-Singaporean medical technology company Osteopore Limited (ASX: OSX; Osteopore or Company) is pleased to announce that it has signed a non-binding term sheet (Term Sheet) with CellHeal Pty Ltd (CellHeal), a biopharmaceutical company focusing on Cell Gene Therapy (CGT) and the discovery and advancement of immunotherapeutic solutions for chronic infectious diseases and cancer.


Highlights

  • Term Sheet to negotiate a licensing agreement with CellHeal to setup manufacturing facilities, attain regulatory approvals and commercialise select Osteopore regenerative medicine technology applications in China.
  • CellHeal commits to raising AUD 10 million to fund commercialisation activities in China.
  • The Term Sheet includes a proposed royalty per product of 10-20% for Osteopore as a percentage of net sales.
  • The partnership with CellHeal paves the way for greater market penetration and visibility in China for Osteopore’s regenerative medicine technology.
  • Osteopore and CellHeal working towards executing a definitive non-exclusive licensing agreement to develop, manufacture and commercialise select applications in China by August 2023.
  • The regenerative medicine market in China was reported to be AUD 5.9 billion in 2021, a 26% year-on-year increase. The market is expected to reach AUD 19.2 billion by 2030 with a CAGR of 13-15%1.

The Term Sheet provides a framework to negotiate definitive agreements for the licensing of select Osteopore intellectual properties (IP) and technologies – 3D printed biomaterials for bone, cartilage and tissue regeneration – to CellHeal, a recognised partner that specialises in commercialising products for entry into the Chinese market.

Melbourne-based CellHeal is seeking to commercialise Osteopore’s regenerative medicine technology in both China and Macau. Although Osteopore’s products do not currently have regulatory approval in China or Macau, the Company’s products can be marketed and sold in Hong Kong and Taiwan.

Subject to the terms of this Term Sheet, CellHeal commits to raising approximately AUD 10 million to strengthen Osteopore’s commercialisation efforts in China. Funds would be allocated to the setup of manufacturing facilities, clinical trials, attaining regulatory approvals and launching Osteopore’s products in China.

Osteopore will work towards negotiating a royalty with CellHeal for each product as a percentage of net sales, subject to due diligence and detailed market research. The percentage is expected to be within the range of 10-20%.

CellHeal would set up a Good Manufacturing Practice (GMP) manufacturing facility in China to manufacture Osteopore products, attain regulatory approvals and commercialise nose and dental applications relating to bone, cartilage and tissue regeneration.

Osteopore would provide CellHeal with a non-exclusive royalty-bearing licence to develop, manufacture and commercialise the Company’s groundbreaking technology across China and Macau. Osteopore would also provide equipment, consumables, management and consultation services to assist with manufacturing setup.

Upon the manufacturing facility being completed and meeting necessary requirements, Osteopore intends to order A$600,000 worth of products manufactured from the facility each year from CellHeal, at Osteopore’s wholesale price with a 10% administration fee on each order. The period over which this order is fulfilled will depend on the number of products required by Osteopore.

Unlocking growth through licensing to capture value in the growing cell therapy market

The partnership marks a transformational opportunity for Osteopore to license its pioneering technology to a proven partner in CellHeal, and in doing so transfer the Company’s innovation to China.

Licensing Osteopore’s innovative technology to CellHeal could enable faster market penetration and unlock strategic advantages for the Company, including the ability to capitalise on Osteopore IP and leverage CellHeal's resources, capabilities and market access. In partnering with CellHeal, Osteopore would gain access to the Company’s customer base, distribution channels and research resources, which could pave the way for global expansion, business growth and new revenue streams for Osteopore.

Osteopore's technology has the potential to complement other products and therapies to enhance clinical healing outcomes. The cell therapy market - comprising both autologous and non-autologous treatments - is projected to reach AUD 67 billion by 2030 at a compound annual growth rate (CAGR) of 14.5% from 2022 to 20302

The scope of the Term Sheet, subject to the execution of license agreements, is detailed below:

  • Field of Use: Commercial applications in the nose and dental regions, relating to bone, cartilage and tendon tissue regeneration and any other Fields of Use agreed between Osteopore and Licensee, from time to time.
  • Grant of License: Non-exclusive, royalty-bearing license to develop, manufacture, and commercialise OSX technology, either alone or as part of combination products or combination therapies, in all Fields of Use in or for the Licensed Territory.
  • Licensed Territory: Greater China, which includes China, Hong Kong, Macau, and Taiwan.
  • Sublicensing: The Licensee may sublicense its licensing rights to other parties with the prior consent of OSX. The Definitive Agreements will set out the consent regime.
  • Royalties/License Fee & Term: Parties will negotiate definitive agreements for the license fee and term which will be a minimum of 15 years. A royalty for each Licensed Product as a percentage of Net Sales is expected to be 10-20%.
  • Timing: The Parties agree to work towards signing a Definitive Agreement before 30 August 2023. This Term Sheet will automatically terminate on 30 September 2023 unless otherwise agreed to by the parties in writing.
  • Funding Conditions: The grant of the licence under this Term Sheet and the obligations on the Licensee to expend money are subject to and conditional on the Licensee securing any necessary third-party funding.
  • Exclusivity and Costs: No exclusivity applies to the negotiations between the parties under the Term Sheet. Each party is responsible for its own costs in connection with the proposed transaction whether it proceeds or not.

Commenting on Osteopore’s expansion to China, Osteopore Executive Chairman Mark Leong said:

“We are thrilled to embark on this strategic partnership with CellHeal as it signifies an important step in Osteopore’s market penetration of China.

This also marks the first time Osteopore have added licensing and royalties to our commercialisation strategy. Together with CellHeal as a strategic partner, Osteopore is making a very significant step into entering the China market with the set up of manufacturing facilities to develop, manufacture and commercialise our groundbreaking implants.

Leveraging the synergies of our expertise, resources and shared vision, we are confident this partnership will unlock opportunities to change lives and expand our footprint.”

Commenting on CellHeal’s strategic partnership with Osteopore, CellHeal Co-Founder Joy Song said:

“CellHeal has the resources, capabilities and market access to bring Osteopore’s life-changing products into Greater China.

Signing the Term Sheet is a key step towards the commercialisation of Osteopore’s pioneering regenerative medicine technology and opens the door to growth opportunities in China.”


Click here for the full ASX Release

This article includes content from Osteopore Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Hand holding smart phone with the Reddit logo in front of tech stock charts.

Reddit Prices IPO at US$34 per Share — What to Know as Trading Begins

Reddit, one of the internet’s most popular discussion forums, is poised to make waves with its much-anticipated initial public offering (IPO) and trading debut, set to happen on Thursday (March 21).

The San Francisco-based company intends to list 22 million shares on the stock market at US$34 each, the high end of its anticipated range of US$31 to US$34. Reddit itself will sell 15.28 million shares, while its existing shareholders will sell 6.72 million shares; the company will not receive proceeds from shares sold by existing shareholders.

Reddit will trade on the New York Stock Exchange under the symbol RDDT.

Keep reading...Show less
Magnificient 7 Stocks on iPhone

Should You Invest in the Magnificent 7?

The so-called "Magnificent 7" stocks have been a hot topic of discussion among investors and financial professionals, with their market activity and record-breaking performances being closely monitored.

However, amid this unprecedented rally, concerns about a potential market drop or correction are looming large as investors try to assess whether the current conditions are sustainable or a harbinger of future volatility.

In this article, the Investing News Network (INN) will explore the topic of the Magnificent 7 and its impact on the stock market and the broader economy.

Keep reading...Show less
smartphone with exposed inner parts

How to Invest in Technology (Updated 2024)

The evolution of technology has undoubtedly grabbed the interest of the general public and investors alike as innovation in diverse categories continues to move forward at a remarkable speed.

Overall, the technology sector has come a long way in the last two decades. In March 2000, the S&P 500's (INDEXSP:.INX) technology index hit its peak of 988.49 points, rising by almost 500 points in the five years leading up to the dotcom bubble. Similarly, the NASDAQ reached an all-time high of 5,000 points during this milestone period.

As of March 2024, the S&P 500's technology index had grown by more than 500 percent, while the NASDAQ had more than tripled. The tech market is now dominated by large players, with companies like Meta Platforms (NASDAQ:META), Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), Netflix (NASDAQ:NFLX) and Alphabet (NASDAQ:GOOGL) creating vast monopolies.

Keep reading...Show less
robot hand and stock chart

5 Biggest ASX Technology ETFs in 2024

It's indisputable that we're in an era of technology and our technological capabilities are exponentially increasing.

If you aren't reading this on a personal computer or laptop — unthinkable in 1970 — you're probably using a smartphone, and phones that can access the internet have only been around since 1996. For a further example, Apple's (NASDAQ:AAPL) meteoric rise is just as well known and needs no elaboration. The fact of the matter is that technology is integral to our life and advancements in the industry are shaping the future.

For any investor, the tech sector may be a desirable investment opportunity, and ETFs can be a safer way to get into an industry. For those unfamiliar, an ETF, or exchange-traded fund, is a basket of securities that is traded like a stock on an exchange and comes in many different types — market ETFs, foreign market ETFs, commodity ETFs and so on. Advantages include lower expense ratios, diversification and fewer broker commissions. One disadvantage is a low level of liquidity.

Keep reading...Show less
SensOre

Heritage Clearances Received for Priority Drill Targets at Abbotts North

Premier1 Lithium (ASX:PLC) (“Premier1” or the “Company”) is pleased to announce that heritage clearances have been received for the first stage of the exploration drilling program at the Company’s Abbotts North Project located 35km north of Meekatharra, Western Australia.

Keep reading...Show less
SensOre

Quarterly Activities Report to 31 December 2023

SensOre Limited (ASX: S3N or the Company), soon to be renamed Premier1 Lithium (ASX:P1L), is focused on tapping into the potential of Western Australia’s renowned lithium reserves. Its strategic exploration approach in this world-class mining jurisdiction is driven by a commitment to uncover valuable resources efficiently and effectively.

Keep reading...Show less

Latest Press Releases

Related News

×